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PULMONARY MEDICINE
Laboratory results on presentation revealed a leukocytosis 
of 28,000 cells/mm3 with 92% neutrophils and a platelet 
count of 558 cells/mm3. Electrolytes revealed a 
potassium of 2.9 mEq/L, HCO3 of 22 mEq/L. Liver 
function tests showed an AST/ALT of 119/73 IU/L. Lipase 
was normal. Lactate normal at 1.2 mmol/L. Procalcitonin 
was 0.64 ng/mL (normal < 0.08 ng/mL).
Respiratory pathogen panel nasopharynx swab detected 
human rhinovirus/enterovirus on PCR. Blood cultures 
showed no growth. Influenza A/B, RSV PCR nasal swab 
was negative. Clostridium difficile toxin DNA, and gastro-
intestinal stool infectious panel were negative. HIV 
antibody and antigen combination were non-reactive. 
Streptococcus pneumoniae and Legionella antigen urine 
CASE DESCRIPTION
This is a case of a woman presenting with four days of 
diarrhea and dyspnea found to have E-cigarette or vaping-
associated lung injury (EVALI).
The patient is a 30-year-old woman who presented to the 
hospital with a chief complaint of dyspnea on exertion. 
She developed dyspnea seven days prior to presentation; 
it was minimal at rest, however symptoms worsened with 
exertion. Her symptoms included fevers, intermittent 
chills, night sweats, dry persistent cough, and four days of 
profuse, watery diarrhea. She did not have sinus pain or 
congestion, headaches, or sore throat. Due to bloody 
diarrhea she sought medical care.
The patient had no allergies and took no medications 
regularly. She had a history of exercised-induced asthma 
during childhood that had resolved. Surgical history was 
notable for seven surgeries for bilateral breast 
fibroadenomas. Family history was notable for 
BRCA-negative breast cancer in her mother.
She works as a real estate agent, with no known specific 
exposures. Ten days prior to admission, she had spent 
time with her nephew who she reported as having several 
symptoms consistent with an upper respiratory infection. 
She does not smoke cigarettes. She had been using 
electronic cigarettes with marijuana for 6 months earlier 
in the year, however due to news reports, she had recently 
stopped. She would smoke marijuana from electronic 
cigarettes four days a week with cartridges lasting about 
one week. Patient used no other drugs or alcohol. No 
history of homelessness or incarceration. Patient is 
sexually active with one male partner with no prior HIV or 
sexually transmitted infections (STI). On review of systems, 
patient noted to have an unintentional 5-pound weight 
loss over the past one week.
On initial vital signs, she had temperature of 38.2 C, HR of 
117 bpm, blood pressure of 108/74 mmHg, respiratory 
rate of 22 breaths/minute, 86% on ambient air and 95% 
on 2 liters nasal cannula of oxygen. She was admitted to 
the medical service due to a new oxygen requirement.
Physical exam was notable for of a well-developed and 
nourished adult female in no acute distress on nasal 
cannula able to speak in full sentences. Pulmonary exam 
showed scattered rales with no wheezing. She had 
tachycardia with no jugular venous distention. She had no 
abdominal pain or lower extremity swelling.
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Figure 1. High-resolution CT of the chest demonstrating diffuse ground-glass 
opacities with septal thickening. There is a peripheral predilection with 
subpleural sparring disease.
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test were negative. Urine pregnancy test was negative. 
Urine drug screen was positive for cannabinoid.
Chest x-ray on initial evaluation revealed diffuse patchy 
bilateral opacities with no effusions. Right upper quadrant 
ultrasound was normal. 
Patient was admitted and placed on azithromycin and 
ceftriaxone for community-acquired pneumonia. 
Subsequently was changed to levofloxacin 750 mg oral. 
Due to continued oxygen desaturation on ambient air, 
intermittent fevers, and tachycardia for two-day duration 
despite antibiotics and supportive care a high-resolution 
computed topography (HRCT) of the chest was obtained.
HRCT demonstrated widespread ground glass opacities 
and scattered septal thickening bilaterally without lobar 
predominance, with diffuse subpleural sparing (Figure 1). 
There were dense consolidations seen in the bilateral lobes 
and the right middle lobe. These findings were consistent 
with inhalation-induced lung injury as well as viral and 
atypical pneumoniae.
Patient subsequently underwent bronchoscopy. Findings 
notable for normal airway with parenchymal infiltrates. 
Bronchoalveolar lavage (BAL) with a transbronchial biopsy 
were performed. Right middle and left upper lobe BAL 
pathology revealed oil-red O stain showing intracyto-
plasmic lipid droplets in alveolar macrophages consistent 
with lipid laden-macrophages (Figure 2). Transbronchial 
biopsy of the left lingula showed pneumonitis; there was 
interstitial edema, inflammation, mild fibrosis, hyperplasia 
of type II pneumocytes, organizing pneumonia, and 
macrophages in the airspace.
The history, imaging and pathology were felt to be 
consistent with EVALI. Due to this the patient was placed 
on three days of methylprednisone 250 mg every 12 
hours. Upon the second day of this regimen, she no 
longer had ambulatory desaturation with stable vital signs. 
She finished a seven-day course of antibiotics while 
hospitalized. She was discharged on 40 mg daily of 
prednisone for with subsequent pulmonary medicine 
outpatient visit, which has not yet occurred.
DISCUSSION
EVALI is lung injury due to the inhalation of non-combustible 
aerosol containing “nicotine, flavors, propylene glycol, and 
vegetable glycerin”, which includes battery operated 
devices that include electronic cigarettes (e-cigarettes).1 
EVALI is becoming a more prevalent, being formally 
recognized in 2019, with over 2,000 cases reported in the 
United States by the Center for Disease Control (CDC).2,3 
This new clinical entity has led to interest in the 
pathogenesis of EVALI. Though no single agent has been 
implicated in the pathogenesis of EVALI, many patients 
have used nicotine, tetrahydrocannabinol (THC), and 
cannabinoid (CBD) oils.2,4  Another agent of interest 
implicated in in the pathogenesis of EVALI is vitamin E 
acetate, which has been associated with impairment of 
pulmonary surfactant.5,6
EVALI is a type of acute lung-injury presenting with a 
wide-range of pulmonary complaints and findings. The 
most common presenting symptoms fevers, tachycardiac, 
and tachypnea.4 One review revealed gastrointestinal 
symptoms in about 80% of patients. In this same review, 
67% of patients presented with hypoxemia, and about 30% 
of patients had oxygen saturation less than 88%.4 Chest 
imaging generally reveals marked bilateral opacities. The 
typical chest CT finding is ground glass opacities marked 
by subpleural sparing.4,7 These findings, however, can be 
seen in other pathological process and thus may warrant 
Figure 2. On the left, Romanowski stain showing numerous alveolar macrophages with abundant vacuolated cytoplasm. On the right, positive orange-
stained droplets within the cytoplasmic vacuoles of alveolar macrophages.
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further investigations with bronchoscopy and BAL. EVALI 
leads to alveolar damage and fibrinous pneumonitis and 
has a wide range of histopathological findings. Most 
reported cases involve variation in cell counts from BAL, 
though usually with a predominance of neutrophils.4 Many 
cases report Oil-red-O staining lipid-laden macrophages 
as in this patient.8
One confounding variable in this case was a positive 
rhinovirus/enterovirus test, which could explain some of 
her symptoms. However, it is unlikely that this viral infection 
would have produced such significant clinical decompen-
sation in an otherwise young and healthy patient. Moreover, 
clinical history, ground glass opacities with subpleural 
sparing, and lipid-laden macrophages with pneumonitis 
are consistent with our current understanding of EVALI.
CONCLUSION
In patients who present with respiratory complaints and 
history of E-cigarettes, EVALI should be strongly 
considered. This is particularly true in those with 
hypoxemia and respiratory distress. A chest CT is an 
Important diagnostic modality to help identify and 
inhalation pattern injury, but many patients may need 
further testing with bronchoscopy and BAL. We presented 
a case of a young, healthy patient who had significant 
respiratory distress secondary to EVALI.
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